Real-world data on metastatic breast cancer in Goiânia, Brazil: a 17-year analysis (19952011)
Mastology (Online)
; 32: 1-10, 2022.
Article
en En
|
LILACS-Express
| LILACS
| ID: biblio-1380407
Biblioteca responsable:
BR2499.9
ABSTRACT
Introduction:
Most of the data on metastatic breast cancer (MBC) originate from hospital-based studies or controlled trials involving specific populations and controlled treatments. In this respect, few population-based studies have analyzed the profile of MBC in low- and middle-income countries.Objective:
To describe the epidemiological profile of women with de novo MBC using data from a population-based cancer registry (PBCR).Methods:
An ecological study conducted in a PBCR in Goiânia, Brazil, for the 19952011 period. Women with MBC at diagnosis were included and the standardized incidence rate and annual percent change (APC) over the period were calculated. The women's clinical and demographic characteristics and data on diagnosis and treatment were analyzed.Results:
Overall, 5,289 cases of breast cancer were registered in the Goiânia PBCR, 277 (5.2%) at metastatic stage. The adjusted incidence was 8.9/100,000 in 1995 and 6.04/100,000 in 2011 (APC 1.1; p=0.6). Most of the patients (70.3%) were receiving care within the public healthcare system and the mean age at diagnosis was 54.7±14.5 years. Additional data for a subpopulation of 156 patients were identified at the city's two main treatment centers. According to immunohistochemistry, 53 women (67.1%) had hormone receptor-positive cancer. Of these, 14.0% (6/43) received endocrine therapy as first-line systemic treatment and 48.5% (17/35) as second-line treatment. A comparison of clinical data between the 19952003 and 20042011 periods revealed no significant differences in age, histological grade, locoregional staging, the presence of symptoms at diagnosis, or in treatment.Conclusion:
This study population of women with MBC consisted predominantly of locally advanced tumors and the luminal-like subtype. The incidence rate of MBC in Goiânia did not change over the 17-year period. Most cases received chemotherapy as firstline systemic treatment irrespective of the tumor phenotype.
Índice:
LILACS
Tipo de estudio:
Prognostic_studies
País/Región como asunto:
America do sul
/
Brasil
Idioma:
En
Revista:
Mastology (Online)
Asunto de la revista:
Neoplasias da Mama
Año:
2022
Tipo del documento:
Article